A phase Ib trial combining a personalized neoAg vaccine with PD-1 blockade found durable, neoAg-specific CD4+ and CD8+ T cell responses in all 82 treated patients, and T cells migrated to metastatic tumors and mediated tumor cell killing (258). This evidence concerns the gene CD8A and neoplasm.